Short acting GLP-1 receptor agonist (injectable)

Lixisenatide 20 µg injection

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

LIXI_SC_20UG_OTHER

Mechanism: GLP-1 receptor agonist; exenatide twice daily and lixisenatide (half life about 2 to 4 hours); beinaglutide (recombinant human GLP-1; half life of minutes)
Trials: 0
Participants in these arms: 0

All doses pooled: Lixisenatide injection
Lixisenatide 20 ug subcutaneous once daily
Lixisenatide 5 µg injection once daily
Lixisenatide 10 µg injection once daily
Lixisenatide 30 µg injection once daily
Lixisenatide 5 µg injection twice daily
Lixisenatide 10 µg injection twice daily
Lixisenatide 20 µg injection twice daily
Lixisenatide 30 µg injection twice daily
Lixisenatide 10 µg injection
Lixisenatide 2.5 µg injection
Lixisenatide 5 µg injection

Lixisenatide 20 µg injection

Related

Trials